---
title: Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer
nct_id: NCT07184957
overall_status: RECRUITING
sponsor: NYU Langone Health
study_type: OBSERVATIONAL
primary_condition: Prostate Cancer
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07184957.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07184957"
ct_last_update_post_date: 2025-09-22
last_seen_at: "2026-05-12T07:14:58.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer

**NCT ID:** [NCT07184957](https://clinicaltrials.gov/study/NCT07184957)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1000
- **Lead Sponsor:** NYU Langone Health
- **Conditions:** Prostate Cancer
- **Start Date:** 2017-05-01
- **Completion Date:** 2040-12-31
- **CT.gov Last Update:** 2025-09-22

## Brief Summary

This will be a prospectively maintained research database. The purpose is to record baseline parameters and treatment outcomes following of Cryotherapy for ablation of clinically localized prostate cancer.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 85 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy
* Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) will be counseled regarding treatment options. Those selecting focal Cryo prostate ablation will then be offered inclusion into this data collection.

Exclusion Criteria:

* Men that are not diagnosed with prostate cancer.
* Men that are diagnosed with clinically localized prostate cancer, but select other treatment options as their desired treatment.
```

## Arms

- **Men with Prostate Cancer** — Men who receive cryotherapy for ablation of clinically localized prostate cancer.

## Primary Outcomes

- **Treatment Complications** _(time frame: Up to Year 15)_
- **PSA-Progression Free Survival** _(time frame: Up to Year 15)_ — Length of time following cryotherapy for ablation treatment of prostate cancer that a patient lives without their prostate-specific antigen (PSA) levels rising significantly enough to indicate disease recurrence, or without dying from any cause.

## Locations (1)

- NYU Langone Health, New York, New York, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.nyu langone health|new york|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07184957.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07184957*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*